Quasi-VMAT in high-grade glioma radiation therapy

被引:2
|
作者
Fadda, G. [1 ]
Massazza, G. [1 ]
Zucca, S. [1 ]
Durzu, S. [1 ]
Meleddu, G. [1 ]
Possanzini, M. [1 ]
Farace, P. [1 ]
机构
[1] Reg Oncol Hosp, Dept Radiooncol, I-09121 Cagliari, Italy
关键词
Radiotherapy; Organs at risk; Hospital; Radiochemotherapy; Maximum dose; INTENSITY-MODULATED RADIOTHERAPY; CONFORMAL RADIOTHERAPY; PROSTATE-CANCER; PLAN QUALITY; ARC THERAPY; SHOOT IMRT; GLIOBLASTOMA; NUMBER; IMAT;
D O I
10.1007/s00066-012-0296-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
To compare a quasi-volumetric modulated arc therapy (qVMAT) with three-dimensional conformal radiation therapy (3D-CRT) and intensity-modulated radiation therapy (IMRT) for the treatment of high-grade gliomas. The qVMAT technique is a fast method of radiation therapy in which multiple equispaced beams analogous to those in rotation therapy are radiated in succession. This study included 12 patients with a planning target volume (PTV) that overlapped at least one organ at risk (OAR). 3D-CRT was planned using 2-3 non-coplanar beams, whereby the field-in-field technique (FIF) was used to divide each field into 1-3 subfields to shield the OAR. The qVMAT strategy was planned with 15 equispaced beams and IMRT was planned using 9 beams with a total of 80 segments. Inverse planning for qVMAT and IMRT was performed by direct machine parameter optimization (DMPO) to deliver a homogenous dose distribution of 60 Gy within the PTV and simultaneously limit the dose received by the OARs to the recommended values. Finally, the effect of introducing a maximum dose objective (max. dose < 54 Gy) for a virtual OAR in the form of a 0.5 cm ring around the PTV was investigated. The qVMAT method gave rise to significantly improved PTV95% and conformity index (CI) values in comparison to 3D-CRT (PTV95% = 90.7 % vs. 82.0 %; CI = 0.79 vs. 0.74, respectively). A further improvement was achieved by IMRT (PTV95% = 94.4 %, CI = 0.78). In qVMAT and IMRT, the addition of a 0.5 cm ring around the PTV produced a significant increase in CI (0.87 and 0.88, respectively), but dosage homogeneity within the PTV was considerably reduced (PTV95% = 88.5 % and 92.3 %, respectively). The time required for qVMAT dose delivery was similar to that required using 3D-CRT. These findings suggest that qVMAT should be preferred to 3D-CRT for the treatment of high-grade gliomas. The qVMAT method could be applied in hospitals, for example, which have limited departmental resources and are not equipped with systems capable of VMAT delivery.
引用
收藏
页码:367 / 371
页数:5
相关论文
共 50 条
  • [41] Coplanar versus noncoplanar intensity-modulated radiation therapy (IMRT) and volumetric-modulated arc therapy (VMAT) treatment planning for fronto-temporal high-grade glioma
    Panet-Raymond, Valerie
    Ansbacher, Will
    Zavgorodni, Sergei
    Bendorffe, Bill
    Nichol, Alan
    Truong, Pauline T.
    Beckham, Wayne
    Vlachaki, Maria
    JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS, 2012, 13 (04): : 44 - 53
  • [42] Vaccines for glioblastoma and high-grade glioma
    Wheeler, Christopher J.
    Black, Keith L.
    EXPERT REVIEW OF VACCINES, 2011, 10 (06) : 875 - 886
  • [43] Targeting the EGFR in high-grade glioma
    Pillay, Vino
    Greenall, Sameer
    Johns, Terrance G.
    CANCER RESEARCH, 2015, 75
  • [44] THROMBOEMBOLISM IN PATIENTS WITH HIGH-GRADE GLIOMA
    QUEVEDO, JF
    BUCKNER, JC
    SCHMIDT, JL
    DINAPOLI, RP
    OFALLON, JR
    MAYO CLINIC PROCEEDINGS, 1994, 69 (04) : 329 - 332
  • [45] Tumor Vaccination for High-Grade Glioma
    Schlegel, Paul G.
    Eyrich, Matthias
    Kramm, Christof
    van Gool, Stefaan
    PEDIATRIC BLOOD & CANCER, 2010, 55 (07) : 1437 - 1437
  • [46] Treatment of high-grade glioma in children
    Betul Cakir, Fatma
    Kebudi, Rejin
    TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY, 2013, 28 (01): : 44 - 50
  • [47] Circulating biomarkers for high-grade glioma
    Loo, Hannah K.
    Mathen, Peter
    Lee, Jennifer
    Camphausen, Kevin
    BIOMARKERS IN MEDICINE, 2019, 13 (03) : 161 - 165
  • [48] Updates in the management of high-grade glioma
    Bradley, David
    Rees, Jeremy
    JOURNAL OF NEUROLOGY, 2014, 261 (04) : 651 - 654
  • [49] Antiangiogenic therapies for high-grade glioma
    Norden, Andrew D.
    Drappatz, Jan
    Wen, Patrick Y.
    NATURE REVIEWS NEUROLOGY, 2009, 5 (11) : 610 - 620
  • [50] Bevacizumab at recurrence in high-grade glioma
    Salmaggi, Andrea
    Gaviani, Paola
    Botturi, Andrea
    Lamperti, Elena
    Simonetti, Giorgia
    Ferrari, Daniela
    Silvani, Antonio
    NEUROLOGICAL SCIENCES, 2011, 32 : S251 - S253